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that crystalloids are used in preference 
to colloids for the resuscitation 
of women with post-partum 
haemorrhage. Nevertheless, during 
the WOMAN trial⁶ we became aware 
that many women with post-partum 
haemorrhage receive colloids and, 
most often, HES. We are concerned 
that the suspension of HES use in 
Europe will lead to intensification of 
efforts to market HES in low-income 
and middle-income countries, and 
that this will mean vulnerable patients, 
particularly women with obstetric 
bleeding, will bear the highest burden 
as a consequence. This is a major 
global health issue, which the WHO is 
uniquely positioned to address.
We seek the support of WHO to 
protect patients by banning the use of 
HES solutions worldwide.
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Hydroxyethyl 
starch solutions and 
patient harm
To the Director General of WHO, 
On Jan 26, 2018, the European 
Medicines Agency (EMA) suspended 
the marketing authorisations of 
hydroxyethyl starch (HES) solutions 
across the European Union.¹ These 
intravenous solutions are often used 
for plasma volume replacement 
following acute blood loss. Evidence 
from high-quality, investigator-
initiated clinical trials in kidney 
donors, patients with sepsis, and in 
critically ill patients has shown that 
HES use is associated with serious 
adverse effects with no patient 
benefits.² Results from experimental 
and clinical studies strongly suggest 
that the toxicity of HES is attributed 
to tissue storage and coagulopathy.³ 
HES-induced coagulopathy increases 
the risk of bleeding and the need for 
blood products in patients with sepsis, 
intensive care patients, and those 
undergoing major surgery.⁴ 
The EMA based the decision not only 
on evidence of harm, but also on the 
fact that the 2013 decision to restrict 
the use of HES to non-septic patients 
with haemorrhagic shock was not 
being observed in many countries. 
HES solutions continued to be used in 
prohibited populations. 
We know that WHO guidelines for 
the prevention and treatment of post-
partum haemorrhage5 recommend 
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to suspend HES is 
hazardous 
In 2013, the European Medicines 
Agency (EMA) restricted the use of 
solutions containing hydroxyethyl-
starch (HES) in critically ill patients 
with sepsis, burns, and impaired 
kidney function while maintaining 
authorisation for the treatment of 
hypovolaemia due to acute blood 
loss when crystalloids alone are not 
sufficient.1 On Jan 12, 2018, the EMA’s 
Pharmacovigilance Risk Assessment 
Committee (PRAC) recommended 
the suspension of HES from the 
European market.2 On Jan 26, the 
EMA’s Coordination Group for Mutual 
Recognition and Decentralised 
Procedures—Human (CMDh) approved 
this recommendation by 15 to 13. 
This decision was based on findings 
from two drug utilisation studies 
highlighting that HES solutions are still 
given to patients with sepsis,3 and after 
auditing of stakeholders and the ad-hoc 
expert committee. 
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acutely ill and perioperative patients. 
The clinical and economic effects of 
this recommendation have not been 
provided. There are insufficient data 
on balanced crystalloids, gelatins, 
dextrans, or albumins to promote 
their use as alternate fluid therapy, 
particularly in surgical, obstetrical, and 
trauma patients.6 HES solutions are 
also widely used in combination with 
albumin as plasma replacement during 
plasmapheresis.7 Their withdrawal 
from the European market will increase 
the use of albumin—a product derived 
from pooled human plasma—and lead 
to cost issues and shortage of albumin 
in many countries. Fourthly, the 
retrospective drug utilisation studies 
have serious limitations—eg, absence 
of appropriate answers when filling in 
the electronic forms, forc ing incorrect 
answers and erroneous classific-
ations of non-adherence. Notably, 
results from the two drug utilisation 
studies already mentioned show that 
adherence to recommended daily 
treatment dose and duration was 
satisfactory, and actual doses and 
durations were substantially lower than 
in studies showing increased AKI and 
mortality.6 Thus, we recom mended 
reappraising existing drug utilisation 
studies and launch ing new studies that 
are better designed. 
Finally, the PRAC has not considered 
the following recommendations 
to enhance consumers’ adherence: 
appending the statement “crystalloids 
alone are not considered sufficient” 
with “in patients treated with 
crystalloids”, clarifying the degree of 
hypovolaemia as acute blood loss of at 
least 500 mL, including an additional 
warning on primary containers (such 
as do not use in sepsis or in critically ill 
patients), distributing with every bag 
of HES a chart to fill in and a patient-
completed medication form, and a 
registry prospectively collecting safety 
data. For these reasons, we strongly 
believe that the EMA recommendation 
to suspend HES is not scientifically 
grounded and is potentially hazardous 
to patients. 
We, attendees of the EMA ad-hoc 
expert meeting held in London on Dec 
18, 2017, recommended to the PRAC 
against suspending HES. This was 
because, firstly, in 2013, results from 
an inter national, industry-independent 
trial4 (in volving 2857 patients with 
acute hypovolaemia in intensive care) 
found no difference in 28-day mortality 
between crystalloids and colloids 
(relative risk [RR] 0·96, 95% CI 0·88 
to 1·04; p=0·26), significantly lower 
90-day mortality in the colloids group 
(0·92, 0·86 to 0·99; p=0·03), and more 
vasopressor-free days (mean difference 
1·04, 95% CI –0·04 to 2·10; p=0·03) and 
ventilator-free days (1·10, 0·14 to 2·06; 
p=0·01) by day 28. The study found no 
evidence that colloids increased risk of 
acute kidney injury (AKI) or any other 
serious adverse event. Analyses of 
long-term outcomes from the CHEST 
trial5 reported no difference in mortality 
between patients who received HES 
and patients who received saline at 6 
and 24 months, as well as a comparable 
mean number of quality-adjusted life-
years gained. Results from a systematic 
review6 of 32 trials and 16 647 patients 
showed that administration of colloids 
did not increase mortality in critically 
ill, trauma, and surgical patients (odds 
ratio [OR] 0·99, 95% CI 0·92 to 1·06). 
In surgical patients, colloids did not 
increase the risk of AKI (p=0·43) or 
renal replacement therapy (p=0·66). 
In trauma patients, the OR of AKI was 
0·46 (95% CI 0·23 to 0·92) in favour 
of colloids. Thus, there is no evidence 
to support suspending HES. Secondly, 
three ongoing trials (EudraCT numbers 
2016-002176-27,  2016-002-163-30, 
and 2014-005575-84) are comparing 
HES to crystalloids (two upon request 
by the PRAC and one funded by the 
French Agency for Medicines and 
Health Products), and will inform 
practice in trauma and in patients 
having abdominal surgery. Thirdly, 
the PRAC has not considered our 
warning that suspending HES might 
result in serious unmet medical needs 
when crystalloids are not sufficient, 













738 www.thelancet.com   Vol 391   February 24, 2018
Universal health 
coverage is needed to 
deliver NCD control 
President Vázquez and Tedros 
Ghebreyesus (Sept 23, p 1473)1 
rightly highlight the urgent global 
need for fiscal, trade, environmental, 
and political actions against non-
communicable diseases (NCDs). Sania 
Nishtar suggests that scope exists 
for a new NCD agency because such 
diseases “have exploded around the 
world”.2 However, hyperbole around 
NCDs is unhelpful. Premature NCD 
mortality (ie, mortality in individuals 
aged 30–69 years) is estimated to be 
decreasing across all sociodemographic 
quintiles (figure). Simultaneously, 
middle and late adult age groups are 
facing rapid demographic expansion 
worldwide, partly due to health and 
develop ment successes that are extend-
ing life expectancy. The biological risk 
of NCDs increases with age. Therefore, 
as populations age, the prevalence 
of NCDs increases, and subsequently 
demand for treatment and the number 
of NCD-related deaths increase.
Global successes against infectious 
and external causes of death postpone 
eventual mortality into age groups 
in which NCDs are the primary risk. 
Therefore, because everyone will die 
of something eventually, and the 
individual chance of an NCD causing 
death increases with age, the number of 
NCD-related deaths is likely to increase. 
Thus, NCDs will never be eradicated. 
However, the WHO 25×25 strategy4 
and Sustainable Development Goal 3.45 
wisely target premature NCD mortality. 
Decreases in premature NCD mortality 
probably reflect decreased exposure to 
risks, improved disease management, 
and healthier lifestyles. NCD risk 
factors need to be reduced further 
and improvements in clinical care 
and health promotion are needed to 
successfully decrease the burden of 
NCDs. One consequence of galvanising 
political will for universal health 
coverage—as championed by Tedros 
and WHO—will be improved action 
against NCDs. Establishing a separate 
NCD agency would add confusion to 
this central aim.
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Figure: Global Burden of Disease3 estimates of mortality due to non-communicable diseases in the 
30–69 year age group between 1990 and 2016
SDI=Socio-Demographic Index.
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Women helping women 
prevent HIV in resource-
limited settings 
Almost a third of the total HIV-infected 
population in Nepal are women, and 
this female population is the fastest 
growing HIV-infected population in 
the rural areas of Nepal.1 Along with 
illiteracy and poverty, gender inequality 
and an inability to successfully 
negotiate safer sex with their partners 
have been noted as reasons for the 
increase in the burden of HIV among 
women.2 Realising that they are at risk 
of HIV infection because of sociocultural 
factors, women in rural areas of Nepal 
are helping to prevent HIV at the 
local level; however, their role in HIV 
prevention is often unrecognised. In 
this Correspondence, I want to highlight 
how local women, individually or 
in groups, are helping each other to 
prevent HIV in rural areas of Nepal.
Firstly, across Nepal women have 
formed non-partisan groups to 
meet every month and discuss the 
empowerment and mobilisation of 
women and the alleviation of poverty.3 
These groups also discuss and learn 
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